Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors

International Journal of Gynecological Pathology

Volumn 31, Issue 6, 2012, Pages 507-516

  Zannoni, Gian Franco ^a   Morassi, Francesca ^a   Prisco, Maria Grazia ^b   De Stefano, Ilaria ^b   Vellone, Valerio Gaetano ^a,b   Arena, Vincenzo ^a   Scambia, Giovanni ^b   Gallo, Daniela ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

ER ; HER2 neu; Ki67; Ovarian cancer; p53; PR

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CLEAR CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, CLEAR CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84867399709     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182518557     Document Type: Article

References (52)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society 2010. Available at: Fttp://www.cancer.org/acs/groups/ content/@nho/documents/ document/acspc-024113.pdf.
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29. Review.
4. Shih IeM, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
5. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-42.
6. Kurman RJ, ShihIe M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
7. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
8. Yoshida S, Furukawa N, Haruta S, et al. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives. Cancer Treat Rev 2009;35:608-15.
9. Anglesio MS, Carey MS, Kö bel M, et al. Clear cell carcinoma of the ovary: A report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol 2011;121:407-15.
10. Kurman RJ, ShihIe M. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60.
11. Zhao C, Wu LS, Barner R. Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: Clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer 2011;2:94-106.
12. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010;29:1741-52.
13. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
14. Guan B, Wang TL, ShihIe M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71:6718-27.
15. Lee KR, Tavassoli FA, Prat J, et al. Surface epithelial-stromal tumours (in Ch. 2: Tumours of the ovary and peritoneum). In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:117-45.
16. Malpica A. Grading of ovarian cancer: A histotype-specific approach. Int J Gynecol Pathol 2008;27:175-81. Review.
17. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504.
18. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995;75:81-6.
19. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009;374:1371-82.
20. De Stefano I, Zannoni GF, Prisco MG, et al. Cytoplasmic expression of estrogen receptor beta (ERb) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 2011;122:573-9.
21. Hayat MA. Estrogens. Microscopy, Immunohistochemistry, and Antigen Retrieval Methods for Light and Electron Microscopy. New York, NY: Kluwer Academic/Plenum Publishers; 2002:276-7.
22. von Wasielewski R, Mengel M, Wiese B, et al. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 2002; 118:675-82.
23. Burges A, Brü ning A, Dannenmann C, et al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2010; 281:511-7.
24. DAKO A/S, F.Hoffmann-La Roche Ltd (eds) (2002). Atlas of interpretation of HercepTestTM Staining (2000).
25. Wolff AC, Hammond ME, Schwartz JM, et al. American Society of Clinical Oncology/College of American Pathologist guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45.
26. Pauletti C, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
27. Cho KR. Ovarian cancer update: Lessons from morphology, molecules, and mice. Arch Pathol Lab Med 2009;133:1775-81.
28. Kurman RJ, ShihIe M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 2011;42:918-31.
29. Kuo KT, Mao TL, Chen X, et al. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010;16:1997-2008.
30. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-601.
31. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: Possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60:7052-6.
32. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-7.
33. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: A continuing enigma. J Clin Pathol 2007;60:355-60. Review.
34. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998;29:551-8.
35. Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001;25:667-72.
36. Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008;27:161-74.
37. Shaaban AM, Green AR, Karthik S, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35.
38. Leung YK, Lam HM,Wu S, et al. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 2010;17:675-89.
39. Stabile LP, Dacic S, Land SR, et al. Combined analysis of estrogen receptor {beta}-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 2011;17:154-64.
40. Zannoni GF, Mg Prisco, Vellone VG, et al. Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma: A pilot study. Histopathology 2011;58:265-75.
41. Zannoni GF, Prisco MG, Vellone VG, et al. Cytoplasmic expression of estrogen receptor beta (ERb) as a prognostic factor in vulvar squamous cell carcinoma in elderly women. Histopathology 2011;59:909-17.
42. Pietras RJ, Má rquez-Garba'n DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007;13:4672-6.
43. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364: 1789-99.
44. Brandenberger AW, Lebovic DI, Tee MK, et al. Oestrogen receptor (ER)-a and ER-b isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod 1999; 5:651-5.
45. Attia GR, Zeitoun K, Edwards D, et al. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000;85:2897-902.
46. Bulun SE, Cheng YH, Yin P, et al. Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Mol Cell Endocrinol 2006;248:94-103.
47. Hudelist G, Keckstein J, Czerwenka K, et al. Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis. Fertil Steril 2005;84(SUPPL2): 1249-56.
48. Xue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 2007;77:681-7.
49. Irving JA, Clement PB. Diseases of the peritoneum. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York: Springer; 2011:661-3.
50. Serrano-Olvera A, Duen as-Gonzá lez A, Gallardo-Rincó n D, et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006;32:180-90.
51. Cloven NG, Kyshtoobayeva A, Burger RA, et al. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004;92:160-6.
52. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann. Oncol 2001;12:S81-7.